Following the observation that TIGIT and PD-1 are coexpressed in the intratumoral T-cells of NHL patients [291] and the favourable results of the combination of anti-TIGIT and anti-PD-1/PD-L1 in preclinical models and some clinical trials for solid cancers [289,294], the combination will, most likely, be evaluated in NHL patients in future clinical trials. This evidence concerns the gene PDCD1 and non-Hodgkin lymphoma.